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Abstract: A medium-throughput screen using Mycobacterium tuberculosis H37Rv was employed to
screen an in-house library of structurally diverse compounds for antimycobacterial activity. In this
initial screen, eleven 7-substituted coumarin derivatives with confirmed monoamine oxidase-B and
cholinesterase inhibitory activities, demonstrated growth inhibition of more than 50% at 50 µM.
This prompted further exploration of all the 7-substituted coumarins in our library. Four compounds
showed promising MIC99 values of 8.31–29.70 µM and 44.15–57.17 µM on M. tuberculosis H37Rv
in independent assays using GAST-Fe and 7H9+OADC media, respectively. These compounds
were found to bind to albumin, which may explain the variations in MIC between the two assays.
Preliminary data showed that they were able to maintain their activity in fluoroquinolone resistant
mycobacteria. Structure-activity relationships indicated that structural modification on position 4
and/or 7 of the coumarin scaffold could direct the selectivity towards either the inhibition of neuronal
enzymes or the antimycobacterial effect. Moderate cytotoxicities were observed for these compounds
and slight selectivity towards mycobacteria was indicated. Further neuroprotective assays showed
significant neuroprotection for selected compounds irrespective of their neuronal enzyme inhibitory
properties. These coumarin molecules are thus interesting lead compounds that may provide insight
into the design of new antimicrobacterial and neuroprotective agents.
Keywords: coumarin; Mycobacterium tuberculosis; cholinesterase inhibitor; monoamine oxidase B
inhibitor; structure-activity relationship; albumin binding; neuroprotection
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1. Introduction
Progressive development of resistance to various chemotherapeutic agents used in the
management of infectious diseases presents a very serious problem in global public health.
Natural products have yielded various classes of effective antimicrobials over the last few decades and
continue to play a large role in the identification of novel lead molecules for this purpose [1].
A large variety of coumarin derivatives have been isolated from natural products and an array
of pharmacological activities have been described for these compounds, as well as related synthetic
coumarins [2,3]. The ability of the coumarin moiety to form several possible interactions with a
particular binding site (including hydrogen bonds, electrostatic, pi–pi and hydrophobic interactions)
likely stabilize target binding and contribute to the versatile pharmacological profile of coumarin
derivatives. Both the type and placement of functional groups on the coumarin scaffold determine the
specific activity of a given derivative [2–4].
Antibacterial and more specifically, antimycobacterial activity are amongst the pharmacological
effects that have been described for a range of structurally diverse coumarin derivatives.
One prominent example of a coumarin-based antibacterial is novobiocin. Novobiocin, the structurally
related chlorobiocin as well as coumermycin A1 are 3-amino-4,7-dihydroxycoumarin derivatives,
alternatively referred to as the classical aminocoumarin antibiotics. Classical aminocoumarins
act as competitive inhibitors of bacterial topoisomerase, more precisely DNA gyrase [5,6].
Competitive inhibition of DNA gyrase by the classical aminocoumarin antibiotics results from an
overlap in binding sites between the sugar moiety of the aminocoumarins (Figure 1, numbered in blue)
and the adenine ring of adenosine triphosphate (ATP )which is required for the gyrase activity [7].
The non-classical aminocoumarin, simocyclinone D8 (Figure 1), lacks the 7-aminosugar moiety and
inhibits bacterial DNA gyrase through simultaneous binding to two alternate binding pockets via
interactions with the coumarin moiety and a terminal angucyclinone group. Simocyclinone D8 thus has
a unique mechanism of action, despite structural similarities to the standard aminocoumarins [8–10].
Similarly, differences in the binding sites between the fluoroquinolone antibiotics (e.g., moxifloxacin
which primarily inhibits topoisomerase IV but also interacts with gyrase) allow fluoroquinolone
antibiotics to maintain potency in aminocoumarin resistant bacteria and vice versa [5,6,11].
Mycobacterial gyrase, which is a validated drug target in Mycobacterium tuberculosis, is also the likely
target for the fluoroquinolone class antibiotics as M. tuberculosis does not express the topoisomerase IV
enzyme [12].
Apart from an interaction with gyrase, bacterial DNA helicase is another suggested target
of selected coumarin derivatives [13–15]. Like other non-classical coumarin antibiotics, the
7-position on these coumarin derivatives does not contain an amino sugar, but rather a moiety
able to undergo hydrophobic interactions with the target site [13–15]. Compound 22 (Figure 1),
a 4,8–dimethyl-3-propionic acid coumarin derivative with a 2-(4-chloro[1,1-biphenyl]4-yl)ethyl
substitution on the 7-position was the most active helicase inhibitor in this series of 7-substituted
biphenyl coumarin derivatives [14]. In this series, the methyl substitution in position 4 of the coumarin
structure drastically increased the anti-helicase activity of the compounds.
Various reports have been published on coumarin derivatives with antimycobacterial activity.
Although most studies adequately describe and quantify the activity for respective series of coumarin
derivatives, differences in assay methods prevent a direct comparison of antimycobacterial activity of
these molecules. Novobiocin as discussed above, demonstrated a minimum inhibitory concentration
(MIC) of approximately 6.5 µM in the standard laboratory strain of M. tuberculosis, H37Rv [16]. Figure 2
depicts some of the most active compounds in their particular series as evaluated in M. tuberculosis.
Compound 3 [17] was identified as a likely mycobacterial gyrase inhibitor whereas inhibition of
FadD32, an enzyme involved in mycolic acid biosynthesis, was confirmed as target for compound 6 [4].
Mechanisms of action were not suggested for compounds 1 [18], 2 [19], 4 [20] and 5 [21].
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As can be expected for compounds which do not necessarily attain their antimycobacterial effect
through interaction with the same target sites, structural features important for activity differ between
the respective series of compounds. Ultimately, various types and combinations of substitutions on all
but positions 1 and 2 of the coumarin scaffold yielded generally effective antimycobacterials, though
possibly through different mechanisms of action. This versatile nature of the coumarin scaffold may
promote interaction with unique, or possibly multiple targets within the mycobacterial bacilli.
Unfortunately, structure-activity relationships for the activity of various classes of coumarin
derivatives (e.g., central nervous system acting, anticoagulant, and anti-cancer agents) often overlap
with that for potent antimicrobial activity [3,22]. A number of review papers describe the importance
of coumarin compounds in the field of neurodegenerative disorders where they have shown inhibitory
properties towards monoamine oxidases, cholinesterases, β- and γ-secretase, and other targets
involved in the progression of neurodegenerative disorders [23–25]. Similarly, coumarin derivatives
described in this article also demonstrated neuronal enzyme inhibitory properties [26]. Therefore, the
effective utilization of the coumarin scaffold may essentially be hampered by its versatility unless
sufficient selectivity can be ensured. Early identification and structure-activity relationship evaluation
of alternative pharmacological effects, over-and-above standard cytotoxicity assays, may increase the
viability of coumarin-based antimycobacterial and/or neuroprotective agents.
As part of a collaborative project, a number of 7-substituted coumarin derivatives initially
designed and synthesized as multifunctional neuronal enzyme inhibitors [26] were found to exhibit
promising antimycobacterial activity (see Table 1) The compounds, originally designed to incorporate
coumarin structures known to show monoamine oxidase B (MAO-B) inhibition [27] and selected
structural elements of donepezil, a selective acetylcholinesterase (AChE) inhibitor [28], were able
to selectively inhibit human MAO-B as well as electric eel AChE and equine butyrylcholinesterase
(BuChE) [26]. Further evaluation of the structure-activity relationships for selectivity and specific
characteristics of these compounds were therefore required in order to assess the viability of the
compounds as neuronal enzyme inhibitors and/or antimycobacterial clinical agents. This article
describes the antimycobacterial activity, plasma protein binding properties, cytotoxicity and
neuroprotection data for the series of neuronal enzyme inhibitors. Preliminary evaluations on
antimycobacterial activity in drug resistant M. tuberculosis are described and structure-activity
relationships for neuronal enzyme inhibition versus antimycobacterial activity as well as a paired
analysis of the neuroprotective properties of selected derivatives are discussed.
2. Results and Discussion
2.1. Medium Throughput Screen
A medium throughput screen (MTS) of various compounds from the University of the Western
Cape School of Pharmacy drug-design compound library was done to identify novel antimycobacterial
agents. A large proportion of the compounds which demonstrated potential antimycobacterial activity
in the initial MTS, were coumarin derivatives. A total of 11 coumarin derivatives inhibited more
than 50% mycobacterial growth at 50 µM. Table 1 provides the structures and activity of two series of
coumarin derivatives CM1–CM19 identified in the MTS, as classified based on the substitution on the
7-position of the coumarin scaffold. The compound numbering from our library was maintained and
the derivatives sorted in order of potency within their respective series. Antimycobacterial activity
is indicated as the percentage mycobacterial growth on day 5 at 100 µM, 50 µM and 1 µM of the
respective derivatives.
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Series 1 Series 2 
    % M. tuberculosis Growth, Day 5 
Number X R1 R2 R3 100 µM 50 µM 1 µM
Series 1      
CM12 ** N Br CH3 H 3.93 4.35 95.23 
CM14 ** N Br CH3 CN 4.44 4.40 99.53 
CM8 ** CH H CH3 Cl 4.62 5.69 93.59 
CM15 ** N Br CF3 H 4.88 6.68 106.71 
CM11 * N Br H H 4.46 7.05 95.18 
CM9 * CH H CH3 CN 6.19 7.75 92.82 
CM7 * CH H CH3 H 8.18 29.50 95.10 
CM6 CH H H H 15.43 52.71 98.19 
CM13 * N Br CH3 Cl 32.06 42.47 97.03 
Series 2 
CM17 * H CH3 H 19.81 28.65 97.59 
CM2 * Br CH3 H 33.16 40.86 89.98 
CM4 * Br CH3 CN 33.52 44.60 95.27 
CM5 Br CF3 H 56.09 65.04 106.87 
CM19 H CH3 CN 55.44 66.92 98.28 
CM16 H H H 50.66 72.70 97.53 
CM1 Br H H 63.63 79.77 96.28 
CM18 H CH3 Cl 75.52 87.91 97.30 
CM3 Br CH3 Cl 92.86 96.11 97.82 
* Compounds that underwent further analysis; ** Compounds selected for MIC determination. 
Based on this screen, series 1 seems to contain more potent inhibitors of M. tuberculosis with the 
p-bromo-N-benzylpiperizine derivatives demonstrating higher activity than the benzyl substituted 
piperidine derivatives. The exception to this is CM13 with a chloro substitution on the R3 position 
which reduces the antimycobacterial activity of the compound in this whole cell assay. Interestingly 
the chloro substitution on R3 improves the activity in the piperidine type compound, though it should 
be noted that the simultaneous removal of the bromine substitution may have contributed to the 
change in activity. The small activity differences between the 6 most active compounds in series 1 do 
not allow for prediction of structure-activity relationships within this range. It would however seem 
that the p-bromo-N-benzylpiperizine derivatives can tolerate various large and small substitutions in 
position 4 of the coumarin scaffold relatively well. No significant differences in activity were 
observed between the trifluoromethane, methyl or unsubstituted 4-substituted coumarin derivatives 
for this series. This is not the case with series 2, where the trifluoromethyl group in position 4 of the 
coumarin scaffold seems to decrease the activity when compared to a methyl substitution in this 
position. The most active compound in series 2 is the R2-methyl substituted benzyl-ether (CM17) 
followed by a similar bromobenzyl-ether (CM2). Replacement of the hydrogen in position 3 of the 
coumarin scaffold with a nitrile moiety does not seem to influence activity, but a chloro-substitution 
in this position decreases activity similar to what was observed for the p-bromo-N-benzylpiperizine 
derivatives in series 1. The combination of halogens in R1 and R3 with a methyl substitution on R2 
seems to decrease activity in both series 1 and 2. 
Comparison of the compounds evaluated in this study with other antimycobacterial coumarin 
derivatives described in literature (see Figure 2, Section 1) highlighted minor similarities and trends. 
Many of the more active derivatives described in literature only have small groups substituted at 
positions 5, 6, 7 and 8 of the coumarin scaffold whereas the compounds evaluated in this study carry 
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CM8 ** CH H CH3 Cl 4.62 5.69 93.59
CM15 ** N Br CF3 H 4.88 6.68 106.71
CM11 * N Br H H 4.46 7.05 95.18
CM9 * CH H CH3 CN 6.19 7.75 92.82
CM7 * CH H CH3 H 8.18 29.50 95.10
CM6 CH H H H 15.43 52.71 98.19
CM13 * N Br CH3 Cl 32.06 42.47 97.03
Series 2
CM17 * H CH3 H 19.81 28.65 97.59
CM2 * Br CH3 H 33.16 40.86 89.98
CM4 * Br CH3 CN 33.52 44.6 95.27
CM5 Br CF3 H 56.09 65.04 106.87
CM19 H CH3 CN 55.44 66.92 98.28
CM16 H H H 50.66 72.70 97.53
CM1 Br H H 63.63 79.77 96.28
CM18 H CH3 Cl 75.52 87.91 97.30
CM3 Br CH3 Cl 92.86 96.11 97.82
* Compounds that underwent further analysis; ** Compounds selected for MIC determination.
Based on this screen, series 1 seems to contain more potent inhibitors of M. tuberculosis with the
p-bromo-N-benzylpiperizine derivatives demonstrating higher activity than the benzyl substituted
piperidine derivatives. The exception to this is CM13 with a chloro substitution on the R3 position
which reduces the antimycobacterial activity of the compound in this whole cell assay. Interestingly
the chloro substitution on R3 improves the activity in the piperidine type compound, though it should
be noted that the simultaneous removal of the bromine substitution may have contributed to the
change in activity. The small activity differences between the 6 most active compounds in series 1 do
not allow for prediction of structure-activity relationships within this range. It would however seem
that the p-bromo-N-benzylpiperizine derivatives can tolerate various large and small substitutions
in position 4 of the coumarin scaffold relatively well. No significant differences in activity were
observed between the trifluoromethane, methyl or unsubstituted 4-substituted coumarin derivatives
for this series. This is not the case with series 2, where the trifluoromethyl group in position 4 of
the coumarin scaffold seems to decrease the activity when compared to a methyl substitution in this
position. The most active compound in series 2 is the R2-methyl substituted benzyl-ether (CM17)
followed by a similar bromobenzyl-ether (CM2). Replacement of the hydrogen in position 3 of the
coumarin scaffold with a nitrile moiety does not seem to influence activity, but a chloro-substitution
in this position decreases activity similar to what was observed for the p-bromo-N-benzylpiperizine
derivatives in series 1. The combination of halogens in R1 and R3 with a methyl substitution on R2
seems to decrease activity in both series 1 and 2.
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Comparison of the compounds evaluated in this study with other antimycobacterial coumarin
derivatives described in literature (see Figure 2, Section 1) highlighted minor similarities and trends.
Many of the more active derivatives described in literature only have small groups substituted at
positions 5, 6, 7 and 8 of the coumarin scaffold whereas the compounds evaluated in this study
carry the larger substitution at 7 position. Bisubstitution on these positions seems to increase
activity. Compound 1 [18], a 4-substituted sulfonyl-benzoxazole derivative was more active when
substituted with methoxy groups in both the 7 and 8 positions of the coumarin, than single- or
unsubstituted derivatives. Compound 2 [19], a 4-substituted, triazole-linked benzimidazole coumarin
with methyl groups at the 5, 7 or 7, 8 positions on the coumarin scaffold similarly demonstrated
the highest activity in its series. A common trend for most of these derivatives seems to be a
large functional group on position 3 or 4 of the coumarin moiety. Compound 3 [17], bearing a
triazole ring on the 3 position of the coumarin scaffold, was able to achieve an MIC value of 6.5 µM.
Compound 4 [20], also with a large group on position 3, was the most active in a series of 3-substituted
benzocoumarin-pyrimidine hybrid molecules. Series 1 derivatives evaluated in this study likewise
seem to tolerate large substitutions on position 3 with no significant differences in activity between
substituted or unsubstituted derivatives. In addition to substitutions on position 4, compounds 5
and 6 are substituted with larger morpholine-containing moieties in positions 5 and 6 respectively.
Compound 6 [4], bearing a comparatively larger N-benzylmorpholine substitution on the 6-position of
the coumarin scaffold, was previously shown to inhibit mycobacteria through inhibition of FadD32, a
newly validated and promising mycobacterial drug target involved in mycolic acid biosynthesis [29].
Methyl substitutions on positions 5 and 7 were again crucial for activity. The importance of the
methyl moieties may be their influence on the geometrical conformation of the adjoining aryl groups,
indicating conformation-specific target binding [4]. Similar to the piperidine and piperizine derivatives
in series 1 evaluated in this study, compounds 5 and 6 with the larger substitutions on the benzene
ring of the coumarin scaffold were substituted with functional groups able to form hydrogen bonds
with the target site.
The neuronal enzyme structure-activity relationships of the coumarin derivatives in Table 1 were
discussed in detail in our recently published paper [26]. Briefly, the coumarin derivatives substituted
at the 7-position with a N-benzylpiperidine or p-bromo-N-benzylpiperazine (series 1) showed better
multifunctional neuronal inhibitory activities compared to their 7-benzyl only substituted counterparts
(series 2). In addition, the substitution of a nitrile group at position 3 of the coumarin scaffold (CM9
and CM14) improved the multifunctional neuronal inhibitory activities of the compounds in series 1
and the MAO-B activity (CM4 and CM19) in series 2. In both series 1 and 2 substitution at position 4
with a large trifluoromethyl group drastically decreased their neuronal enzymatic activities. It was also
noted that, in general, the N-benzylpiperidine substituted coumarin derivatives showed significantly
improved activities over their p-bromo-N-benzylpiperazine substituted counterparts. From these
studies compound CM9 was identified as the most promising multifunctional neuronal enzyme
inhibitor. It may therefore be possible to increase the selectivity of coumarin derivatives towards either
neuronal enzyme inhibitory activity or antimycobacterial property through selective substitution in
positions 4 and 7 of the coumarin scaffold.
All derivatives in series 1 and 2 that demonstrated more than 50% mycobacterial growth inhibition
at 50 µM were further analysed at narrower concentration ranges using a similar method to the original
MTS. Figure 3 depicts the mycobacterial growth inhibition for compounds CM12 and CM17, which
were the most active in their respective series in the initial screen. Relative fluorescence of the far-red
fluorescent reporter mCHERRY was used as the indicator of growth during this screen which was
performed once to validate the activity found during the initial screen. These graphs show the
inhibitory effect of the compounds compared to the untreated as well as a known antimycobacterial
rifampicin (RIF) at 6 µM. From this activity validation screen CM8, CM12, CM14 and CM15 (all in
series 1) were identified as the most potent compounds and evaluated in further studies to gain insight
into their antimicrobacterial properties.
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Figure 3. Mycobacterial growth inhibition by compounds CM12 (A) and CM17 (B) at narrower
concentration intervals. M. tuberculosis H37Rv:pCHERRY3 was cultured in 96 well plates as described,
with compounds at the concentrations as shown. Experiments were repeated in biological triplicates;
each plot shown here shows a representative biological replicate with the mean and standard deviation
of 3 technical replicates for each data point.
2.2. Evaluation of Compound Activity in Quinolone Resistant Mycobacterium tuberculosis
Various coumarin-based antimicrobials have been shown to target bacterial DNA gyrase, which is
also the suggested target of the fluoroquinolone antibiotics in mycobacteria [5,6,11,12]. It was therefore
decided to evaluate whether the coumarin derivatives evaluated in this study would be able to maintain
potency in fluoroquinolone resistant mycobacteria. The activity of CM12 and CM14 were evaluated
in three strains (Gly88Cys, Ala90Val and Asp94Gly) of M. tuberculosis demonstrating moxifloxacin
resistance. Genetic mutations in quinolone-resistance determining regions (QRDR) of DNA gyrase
are primarily responsible for conferring resistance to various fluoroquinolone antibiotics. Particularly
substitutions in the 94 position are commonly identified in quinolone resistant strains [30]. CM12 and
CM14 maintained potency in all evaluated strains featuring three different mutations in the QRDR
region (see Figure 4). Preliminary investigations indicate that it is likely that compounds in series 1
will maintain activity in fluoroquinolone resistant mycobacteria. Additional evaluations are required
to determine the true extent of activity in resistant strains for series 1 as well as series 2 derivatives.
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Moxifloxacin (MOX) was used at a concentration of 1.2 µM. OD600: optical density measured at 600 nm.
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2.3. Minimum Inhibitory Concentration Determination
MICs of the most active compounds from the initial evaluations (CM8, CM12, CM14, and
CM15) were determined independently at the University of Stellenbosch (US, South Africa) and
University of Cape Town (UCT, South Africa) utilizing different assay methods described in detail
in the methodology section. Briefly, the US assay (similar to the assay used for the MTS), utilized a
H37Rv strain transformed with a plasmid encoding a red fluorescent reporter (pCHERRY3 [31]), a gift
from Tanya Parish (Addgene plasmid # 24659)), in albumin-containing media (Middlebrook 7H9 broth,
Becton, Dickinson and Co., Franklin Lakes, NJ, USA, enriched with 10% oleic albumin dextrose catalase
(OADC), 0.2% glycerol and 0.05% Tween 80; 7H9+OADC). The UCT method utilized a standard broth
microdilution method with M. tuberculosis H37RvMA pMSP12:GFP (green fluorescent protein) in
glycerol-alanine-salts with 0.05% Tween 80 and iron (GAST-Fe) [32]. Consistently lower MICs were
observed in the GFP GAST-Fe assay. CM8, CM12, and CM14 all showed approximately 2- to 3-fold
lower MIC90 values in the UCT laboratory assay with CM15 showing the largest discrepancy with a
14-fold difference between the two methods (Table 2). For the purposes of comparison with standard
antimycobacterials under similar conditions, CM12 and CM14 at 25 µM were able to achieve growth
inhibition in similar ranges to moxifloxacin at 1.2 µM whereas RIF at 6 µM resulted in 100% inhibition
of bacterial growth in the pCHERRY3 assay. RIF has a MIC of 0.0274 µM in the GFP assay.
Table 2. Minimum inhibitory concentrations determined using two methods.
Compound
GFP GAST-Fe mCHERRY—7H9+OADC
MIC90 (µM) MIC99 (µM) MIC90 (µM) St. Dev. MIC99 (µM) St. Dev.
CM8 19.6 25.2 40.55 1.16 44.15 1.37
CM12 14 29.7 40.89 0.06 50.40 8.96
CM14 16.7 28 45.22 3.04 54.46 9.58
CM15 3.2 8.31 43.78 1.46 57.17 10.05
Abbreviations: St. Dev., standard deviation; MIC90, minimum inhibitory concentration required to inihibit 90%
of the organism; MIC99, minimum inhibitory concentration required to inhibit 99% of the organism; GFP, green
fluorescent protein; GAST-Fe, glycerol-alanine-salts with 0.05% Tween 80 and iron; 7H9+OADC, Middlebrook 7H9
broth, enriched with 10% oleic albumin dextrose catalase (OADC), 0.2% glycerol and 0.05% Tween 80.
Although it is relatively common to see differences in MIC between different media types, the
drastic differences, in particularly for compound CM15, warranted further investigation. In the
assay methods used in this study, differences in the observed MIC could be due to the lack and
presence of albumin in GAST-Fe and 7H9+OADC media respectively, the unique reporters used in
the two assays, the difference in inoculum size or alternatively, result directly from the mechanism
of action of the compounds. The size of the inoculum has been shown to influence the MIC of
antimycobacterials. A 10-fold increase in inoculum size resulted in an approximately 4-fold increase
in MIC of bedaquiline [33]. The optical density measured at 600 nm (OD600) of 0.004 and 0.04 for
the GAST-Fe and 7H9+OADC methods respectively, could therefore contribute to the higher MIC
observed using the second method.
Another likely contributor to the observed differences in MIC for the coumarin-based derivatives
may be binding to albumin. Various coumarin derivatives (e.g., warfarin) are known to bind extensively
to blood-soluble proteins. Serum albumins, which are the major soluble protein constituents of the
circulatory system (4% w/v), have the ability to reversibly bind a large variety of exogenous compounds
including fatty acids, amino acids, drugs and pharmaceuticals [34–36]. Plasma protein binding forms
an integral part of distribution and bioavailability for numerous medications currently on the market
but might also become problematic where binding is extensive [37,38]. In vitro, binding to albumin
would reduce the amount of compound available to exert an effect on the mycobacterial cell and in
theory reduce the observed MIC of the derivative. The impact of the albumin binding on in vivo MIC
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of compounds would however depend on the extent and nature of the binding to albumin within
the host.
2.4. Albumin Binding Assay
To better understand the observed differences in MIC between the two assays, we investigated
possible albumin binding for the two coumarin derivatives CM14 and CM15 with the largest
differences in MIC between the GAST-Fe and 7H9+OADC media based assays. Albumin-enriched
media contain approximately 0.5% w/v bovine serum albumin (BSA). Results of previous studies
indicate that human serum albumin (HSA) and BSA are similar proteins in space structure and chemical
composition [39–41]. BSA was therefore selected as a protein model to investigate fluorescence
quenching as an indicator of the extent of interaction between coumarin derivatives CM14 and CM15
and albumin, using fluorescence spectroscopy. Fluorescence quenching is the decrease of the quantum
yield of fluorescence from a fluorophore induced by a variety of molecular interactions with the
quencher molecule. Fluorescence quenching can be dynamic, resulting from collisional encounters
between the fluorophore and quencher, or static, resulting from the formation of a ground state
complex between the fluorophore and quencher [42–44]. The effects of compounds CM14 and CM15
on the fluorescence quenching of BSA, excited at 295 nm are presented in Figure 5.
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Figure 5. The effects of CM14 (A) and CM15 (B) on the fluorescence spectra of BSA at 22 ◦C.
ex = 295 nm; c(BSA) = 1.00 × 10−5 mol L−1; c(Q)/(×10−6 mol L−1). Final concentrations of CM14
and CM15 = 0 × 10−6 mol L−1, 2.5 × 10−6 mol L−1, 5.0 × 10−6 mol L−1, 7.5 × 10−6 mol L−1,
10 × 10−6 mol L−1, 12.5 × 10−6 mol L−1, 15.0 × 10−6 mol L−1, and 17.5 × 10−6 mol L−1.
The e ission spectrum of CM14 showed two maxima, the first one at 335 nm (which is
characteristic for tryptophan in BSA [45]) and the second peak at 400 nm (which is assigned to
fluorescence of compound CM14 at concentrations of 5 × 10−6 mol L−1 and upwards). The emission
spectrum of CM15 only showed a maximum at 335 nm for BSA and a weak emission peak of CM15 at
415 nm at higher concentrations of the compound. The excitation and emission maxima of CM14 and
CM15 are shown in Table 3.
The mechanism of the fluorescent quenching of CM14 and CM15 to BSA is described using the
Stern-Volmer equation:
F0/F = 1 + ksv[Q] = 1 + kq τ0[Q]
where F0 and F are the fluorescence intensities before and af r the addition of the quencher,
respectivel ; ksv is the dynamic quenching constant; kq is the quenching rate constant; [Q] is the
concentration of quencher; τ0 i the averag lifetime of the molecule without quencher and its value is
considered to be 10−8 s [46,47]. The Stern-Volmer plot of the CM14 and CM15 is presented in Figure 6.
The plots show a good linear relationship within the investigated concentrations of CM14 and CM15.
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The results in Table 3 show that kq values were much greater than the limiting diffusion rate
constant of the biomolecule (2.0 × 1010 mol L−1 S−1), which indicated that the probable quenching
mechanism of BSA-CM14 and BSA-CM15 interactions was initiated by complex formation rather than
by dynamic collision [48].
It is evident from the results that the fluorescence intensity of BSA decreases with increasing
concentrations of compounds CM14 and CM15. It can also be concluded that the fluorescence
quenching of tryptophan in BSA as observed for compounds CM14 and CM15 results from complex
formation between the two compounds and BSA. The more extensive decrease in fluorescence
observed at lower concentrations of compound CM15 likely indicate a higher binding affinity between
compound CM15 and albumin. These results indicate that albumin binding likely plays a large role in
the observed differences in activity between the GAST-Fe and 7H9+OADC assays used in this study.
The higher albumin binding affinity of CM15 is likely the reason for the larger MIC variation perceived
for this compound.
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Compound T (◦C) λEx (nm) λEm (nm) ksv (mol L−1) kq (mol L−1 S−1) R2
CM14 22 350
a
350 b
395 a
400 b 3.80 × 10
5 2.63 × 1014 0.9780
CM15 22 335
a
335 b
415 a
415 b 4.88 × 10
5 2.00 × 1014 0.9927
a Measured in Tris-HCl buffer at 1 × 10−6 mol L−1. b Measured in BSA (1 × 10−5 mol L−1) at 1 × 10−6 mol L−1.
Abbreviations: λEx: excitation; λEm: emission; ksv: dynamic quenching constant; kq: quenching rate constant;
R2: coefficient of determination.
In addition to providing more clarity about the observed MICs, albumin binding properties may
also provide some insight into the possible pharmacokinetic behavior of these drugs. Binding and
dissociation of compounds from plasma proteins is a dynamic process with only the unbound fraction
of the drug available to exert an effect. In a clinical setting, the dosage of a drug is calculated to ensure
that, at any point in time, sufficient free drug is available to have the required pharmacological effect.
The same principle would apply to side effects or toxicity and thus, plasma protein binding becomes
an important consideration, particularly in highly bound drugs. In light of the divergent albumin
binding affinities observed in the evaluated compounds, it would likely be more pertinent to utilize
the MIC values obtained in the albumin free GFP-GAST-Fe media for the purposes of determining
structure-activity relationships for antimycobacterial activity. CM15, which seems to be at least 3-fold
more active than the other top compounds in the GFP assay, has a large CF3 substitution on the
4 position of the coumarin scaffold, and a p-bromo-N-benzylpiperizine substitution on C7. Activity
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differences between CM8, CM12 and CM14 are not pronounced enough to draw structure-activity
relationship conclusions.
2.5. Cell Viability Assays
Cytotoxicity assays for the compounds showing the lowest MIC99 (CM8, CM12, CM14, and
CM15) were done on Chinese hamster ovary (CHO) epithelial cells using a standard MTT assay
method (Table 4) [49]. Data was supplemented with further cytotoxicity analysis of CM14 and CM15
as well as CM9 in a similar assay using the neuronal type SH-SY5Y neuroblastoma cells. The SH-SY5Y
cytotoxicity assay results were used to determine the concentration at which the compounds do not
affect the viability of the SH-SY5Y cells in order to determine their neuroprotective effect using the
1-methyl-4-phenyl pyridinium (MPP+) induced neurotoxicity method [50,51].
Table 4. 50% cell viability (CC50) and selectivity indices on Chinese hamster ovary (CHO) cells, cell
viability on SH-SY5Y cells and 50% enzyme inhibition (IC50) of selected test compounds.
CM CC50 µMCHO
SI
GFP a
SI
mCHERRY b
CC 50%
SH-SY5Y c
MAO-A
IC50 µM d
MAO-B
IC50 µM d
AChE IC50
µM d
BuChE IC50
µM d
CM8 33.0 1.31 0.75 ND n.a. 0.29 31.30 1.27
CM9 ND ND ND 10–50 n.a. 0.30 9.10 5.90
CM12 15.5 0.52 0.31 ND n.a. 3.60 12.8 9.70
CM14 41.2 1.47 0.76 50–100 n.a. 1.41 38.5 13.3
CM15 26.3 3.16 0.46 10–50 n.a. 5.64 >100 >100
Emetine 0.06 ND ND ND ND ND ND ND
a Selectivity index (SI) = CC50 CHO/MIC99 GFP-GAST-Fe. b Selectivity index (SI) = CC50 CHO/MIC99
mCHERRY-7H9+OADC. c Inhibition range (uM) where 50% cell toxicity will be observed. d Data taken from
Joubert et al., 2017 [23]. ND = not determined. n.a. = no activity.
CM9 was included in the neuronal cell viability and MPP+ induced neurotoxicity assays because
it was identified previously as the best multifunctional neuronal enzyme inhibitor (50% inhibitory
concentration (IC50): MAO-B = 0.30 µM; AChE = 9.10 µM; BuChE = 5.90 µM) within the series
of coumarin derivatives (Table 4) [23]. CM9 did not show any significant antimycobacterial
activity and was therefore not included in the CHO cytotoxicity assay. CM14 was included
to draw a comparison between the neurotoxicity and potential neuroprotective effect of the
3-nitro-4-methylcoumarin derivatives substituted at the 7-position with either a N-benzylpiperidine
(CM9) or p-bromo-N-piperazine moiety (CM14). CM15, with a large trifluoromethyl substituent
on position 4, showed the most promising antimycobacterial activity with minimal multifunctional
neuronal enzyme inhibitory activity. It was included in the neurotoxicity assays to study the effect
of the neuronal enzyme inhibitory activities, or lack thereof, on the neuroprotective ability of these
compounds or if other mechanisms of action are involved. CM8 and CM12 were not included in
the neurotoxicity assays as their multifunctional neuronal enzyme inhibitory properties were not as
pronounced as CM9 and CM14.
Cytotoxicity (CC50, 50% cytotoxic concentration) observed for CM8, CM12, CM14 and CM15 on
CHO cells was moderate (CC50: 15.5–41.2 µM) indicating low toxicity compared to the cytotoxic agent
emetine (CC50 = 0.06 µM). These compounds however showed low selectivity indices when both the
GFP and mCHERRY MIC99 assay results are compared to the CC50 results (Table 4). The compounds, in
general, were slightly more selective towards the mycobacterial strain when using the GFP assay results,
with CM15 showing the best selectivity (selectivity index (SI) = 3.16). The slight selectivity was however
not retained when the results from the mCHERRY assay were used in the SI calculations. These poor
selectivity indices may limit the further development of these coumarin derivatives. However, the
structure-activity relationships identified in this paper may enable the design of coumarin structures
with improved antimycobacterial activities and subsequently more favourable selectivity indices.
The viability of SHSY-5Y human neuroblastoma cells was assessed at different concentrations
of compounds CM9, CM14 or CM15 (Figure 7A). Treatment with the compounds at 10 µM did not
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significantly affect the viability of the SH-SY5Y cells (p > 0.05). However, at higher concentrations
(50 µM and 100 µM) the viability of the cells were significantly (p < 0.001) affected by the test
compounds, although to a lesser extent by CM14. These results also correlate to the CC50 CHO
values obtained for CM14 and CM15 (Table 4).
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Based on the SH-SY5Y cytotoxicity analysis it was decided that the MPP+ neuroprotection
studies would be done at compound concentrations between 1 µM and 10 µM in order maintain
the viability of the cells. MPP+ is highly toxic to neurons and has been widely used to induce
neurodegeneration in various in vitro and in vivo models [50,51]. Several signaling pathways
have been suggested to be responsible for MPP+-mediated neurotoxicity in SH-SY5Y cells, for
instance, trigger of oxidative stress [52], induction of apoptosis [53], and inactivation of pro-survival
phosphoinositide 3-kinase (PI3-K)/Akt cascade [54–56]. This assay was deemed appropriate to test
for initial neuroprotective ability of CM9, CM14 and CM15 because of the multitude of pathways
involved in MPP+ mediated neurotoxicity and the multifunctional enzyme inhibitory abilities of the
test compounds, especially CM9.
SH-SY5Y cells were exposed to the neurotoxin MPP+ with or without test compound, and cell
viability was evaluated using the MTT mitochondrial function assay [43]. As illustrated in Figure 7B–D,
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after the exposure to 1000 µM MPP+ for 48 h, the cell viability declined significantly to 51.42 ± 3.18%.
However, its cytotoxic effects were ameliorated in the presence of CM9, CM14 and CM15 at 1 µM,
5 µM and 10 µM concentrations. The compounds, at a 1 µM concentration, restored cell survival
to 81.86 ± 3.72%, 101.2 ± 6.00% and 81.05 ± 6.83%, respectively. CM9 showed activity in a dose
dependent manner exerting maximal cytoprotection of 92.2 ± 4.18% at 10 µM. At 5 µM and 10 µM
a slight decrease in cytoprotection was observed for CM14 and CM15. This may indicate that in the
neurotoxin challenged state the SH-SY5Y cells may be more sensitive to the cytotoxic effect of the
test compounds. Therefore, CM14 and CM15 might have enhanced the toxicity of the neurotoxin
which resulted in lower neuroprotection values observed at higher concentrations. Thus, in general
and especially at a 1 µM concentration, these compounds, and particularly CM14, exerted highly
significant cytoprotection towards MPP+ insults to the SH-SY5Y neural cells.
The results of the MPP+ neuroprotection study did not provide any information on
structure-activity relationships of these compounds as CM9, CM14 and CM15 showed similar levels of
cytoprotection. It was however noted that the neuronal enzyme inhibitory activity of these compounds
is not the only factor that play a role in cytoprotection and that other mechanisms of action are involved.
For instance, CM15 showed poor neuronal enzyme inhibitory activities but was still able to significantly
protect the cells from MPP+ induced injury. CM9 with the best multifunctional enzyme inhibitory
profile showed cytoprotection at the same level as CM15. As described in the literature coumarin
derivatives may possess anti-inflammatory, anti-apoptotic and antioxidant effect [2,3]. These effects
combined with the multifunctional neuronal enzyme inhibitory abilities of the compounds may explain
the excellent neuroprotection observed. Therefore, further neuroprotection studies are necessary to
elucidate the mechanism(s) of action of these compounds.
3. Materials and Methods
3.1. Compound Synthesis
Synthesis methods of the compounds described in this article are described in detail in previous
publications by the drug design group at University of the Western Cape (UWC, South Africa) [26].
3.2. Initial Medium Throughput In Vitro Activity Screen
This study was approved by the Stellenbosch University Health Research Ethics Committee
(S15/06/135). The M. tuberculosis H37Rv strain used during this study was obtained from the American
Type Culture Collection (ATCC) (ATCC 27294) and whole genome sequencing [57] and virulence
confirmation in a murine infection model [58] was used to verify the strain. The episomal plasmid
pCHERRY3, a gift from Tanya Parish (Addgene plasmid #24659) [31], which expresses the far-red
fluorescent reporter mCHERRY and contains a hygromycin B resistance cassette, was transformed into
this electrocompetent M. tuberculosis H37Rv. Growth curve analysis of both M. tuberculosis H37Rv and
M. tuberculosis H37Rv:pCHERRY was performed twice to ensure that the plasmid did not have any
deleterious effects on growth.
The antimycobacterial activity of the synthetic compounds was determined using a medium
throughput 96-well plate assay. M. tuberculosis H37Rv with and without the reporter was cultured
in 7H9+OADC, without and with 50 µg/mL hygromycin B respectively, whereafter the culture was
strained (40 µm; Becton, Dickinson, and Co.), and the OD600 was adjusted to 1.0. Culture was added to
each well, resulting in a final OD600 of 0.02. White, flat bottom 96-well microtiter plates were prepared,
with a final volume of 200 µL, final bacterial OD600 of 0.02, and final compound concentration of
100 µM, 50 µM or 1 µM.
Controls included dimethyl sulfoxide (DMSO), positive, negative, and compound control.
The background control, which contains M. tuberculosis H37Rv without the fluorescent reporter
is subtracted from the fluorescence measurements since it displays the inherent fluorescence of
M. tuberculosis H37Rv. Negative control is included as an untreated fluorescence control where
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the DMSO control is included to ensure that the maximum amount of DMSO present in the compound
dilutions does not interfere with growth. The positive control wells contained 6 µM RIF and the
compound controls contained 100 µM compound which was used to confirm that the compound does
not autofluoresce in the absence of M. tuberculosis.
One-hundred microliters of the M. tuberculosis H37Rv:pCHERRY3 diluted culture was added
to each well except the gain, background and compound control wells. In the gain control wells,
100 µL of the undiluted M. tuberculosis H37Rv:pCHERRY3 culture was added and in the background
control wells M. tuberculosis H37Rv without the fluorescent reporter was added. The plates were sealed
with breathable sealing film and incubated at 37 ◦C for 6 days, taking readings on days 0, 2, 3, 4, 5,
and 6 using a BMG Labtech POLARstar Omega plate reader (BMG Labtacch, Offenburg, Germany,
excitation: 587 nm, emission: 610 nm). During the readings the breathable seal was removed and
an optical sealing film was adhered, whereafter it was removed and replaced by a new breathable
sealing film. The average of the background control was subtracted from the fluorescence readings
whereafter the data were visualised using GraphPad Prism v7.01 (GraphPad software, La Jolla, CA,
USA), by plotting the relative fluorescence units (as a measure of growth) over time. The percentage
inhibition was also calculated on day 5, by dividing the treated by the untreated values. Compounds
that inhibited more than 50% growth at 50 µM were selected for further study and screened at narrower
concentration ranges to more accurately ascertain the extent of the compound’s antimycobacterial
activity. The second round of screening was also performed using relative fluorescence as a proxy for
growth. The growth curves were set up similarly to the initial screen. Five compounds which showed
the highest activity during the second screen were selected to undergo further analysis. Of these five
compounds, four were coumarin derivatives.
3.3. Activity in Moxifloxacin Resistant M. tuberculosis
Three M. tuberculosis moxifloxacin resistant mutants, carrying G88C, A90V, or D94G amino acid
changes in gyrase A, were tested for CM12 and CM14 cross-resistance. Moxifloxacin stock solutions
were prepared at a concentration of 25 µM in DMSO and stored at −80 ◦C. The resistant mutants and
an M. tuberculosis H37Rv susceptible strain were prepared as described in Section 3.2 and subsequently
exposed to 1.2 µM moxifloxacin, 25 µM CM12 and 25 µM CM14 in technical triplicates in a black, flat,
clear-bottom 96 well plate. Each well containing the respective strain was inoculated to an OD600 of
0.02 in a final volume of 200 µL. Readings were taken as described in Section 3.2 over 8 days and OD600
was plotted over time using GraphPad Prism v7.01.
3.4. Minimum Inhibitory Concentration Determination
MICs were determined for the four most active coumarin derivatives identified in the MTS.
CM8, CM12, CM14, and CM15 were screened using two independent methods as described below.
3.4.1. M. tuberculosis pMSP12:GFP in GAST-Fe Media
The first MIC determination was performed at the Institute of Infectious Disease and
Molecular Medicine, University of Cape Town (UCT) at a screening facility jointly managed by the
MRC/NHLS/UCT Molecular Mycobacteriology Research Unit (A/Prof Digby Warner) and the H3D
Drug Discovery and Development Unit (Prof Kelly Chibale). Here, the standard broth microdilution
method was performed using M. tuberculosis H37RvMA pMSP12:GFP [32]. A 10 mL culture was
grown in glycerol–alanine–salts with 0.05% Tween 80 and iron (0.05%; GAST-Fe) pH 6.6, to an OD600
of 0.6–0.7. Thereafter the culture was diluted 1:100 in GSAT-Fe. In a 96-well microtiter plate, two-fold
serial dilutions of each compound were prepared in GAST-Fe whereafter 50 µL of the diluted culture
was added to each serial dilution well resulting in an OD600 of 0.004. The plate layout used was
modified from a previously described method [59]. Controls included a bacterial growth control
(5% DMSO in GAST-Fe) and a positive control (0.15 µM RIF). The microtiter plate was incubated at
37 ◦C with 5% CO2 and humidity, sealed within a secondary container. Using a plate reader (FLUOstar
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OPTIMA, BMG Labtech GmbH, Ortenberg, Germany; excitation: 485 nm; emission: 520 nm) relative
fluorescence was measured on days 7 and 14. The CCD Vault from Collaborative Drug Discovery
(Burlingame, CA, USA, www.collaborativedrug.com) was used to archive and analyse the fluorescence
data. Analyses included normalisation to the bacterial growth and antimycobacterial growth control
as the maximum and minimum growth representations respectively generating a dose-response curve
using the Levenberg–Marquardt damped least-squares method. This dose response curve was used to
calculate the MIC90 and MIC99 which is described as the lowest concentration at which the compound
inhibits growth by more than 90% and 99%, respectively.
3.4.2. M. tuberculosis H37Rv:pCHERRY3 in 7H9+OADC
The second technique used a different fluorescent reporter (mCHERRY) and media (7H9+OADC).
Dose-response curve analysis was carried out on the same compounds as above. Dose response curves
were performed by exposing M. tuberculosis H37Rv:pCHERRY3 to increasing concentrations of each
compound in white flat bottom 96 well plates. M. tuberculosis H37Rv with and without mCHERRY
was prepared as described in Section 3.2. In a white, flat bottom 96 well microtiter plate two-fold
serial dilutions of the compounds were prepared with a 100 µL final volume and final bacterial OD600
of 0.04. This method was adapted from a previously described method [59]. The controls included
were a background control (M. tuberculosis H37Rv in 7H9+OADC), a negative control (M. tuberculosis
H37Rv:pCHERRY3 in 7H9+OADC) and a positive control (M. tuberculosis H37Rv:pCHERRY3 in
7H9+OADC containing 2 µM RIF). The microtiter plate was sealed with a breathable film, placed in a
secondary container and incubated at 37 ◦C for 5 days, after which a relative fluorescence measurement
(Excitation: 587 nm; Emission: 610 nm) was taken using a BMG Labtech POLARstar Omega plate
reader. To analyse the relative fluorescence data the average of the background control was subtracted
from each well, and the subsequent data set was analysed in GraphPad Prism v.7.01. Data were first
normalised using built in non-linear dose-response curve analysis. This gave an output of IC50 as well
as a Hill Slope which was used to determine the IC90 and IC99 of each compound. IC90 and IC99 was
defined as the concentration where 90% and 99% of growth was inhibited, respectively.
3.5. Bovine Serum Albumin Binding Assay
The interaction between coumarin derivatives (CM14 and CM15) and BSA were measured
by fluorescence spectroscopy. BSA (≥98%) was obtained from Sigma Aldrich (Kempton Park,
South Africa) and dissolved in a Tris–HCl (0.10 mol L−1, pH = 7.4) buffer to form the BSA solution
with a concentration of 1.00 × 10−5 mol L−1. A Tris–HCl buffer (0.10 mol L−1, pH = 7.4) containing
0.10 mol L−1 NaCl was selected to keep the pH value constant and to maintain the ionic strength
of the solution. CM14 and CM15 stock solution (1.00 × 10−3 mol L−1) was prepared in MeOH.
All other reagents were of analytical grade and double-distilled water was used in the experiments.
Fluorescence spectra were recorded on a Synergy Mx fluorescence plate reader (BioTek, Winooski,
VT, USA). Black 96 well plates were used in all experiments. The excitation and emission slits
were 9 nm. Fluorescence spectra were measured in the range of 315–500 nm at the excitation
wavelength of 295 nm. All experiments were done at 22 ◦C. The assay was conducted using a
200 µL solution containing 1.00 × 10−5 mol L−1 BSA that was titrated by successive additions of
1.00 × 10−3 mol L−1 coumarin CM14 or CM15 solution. The final concentration of the compounds
varied from 0 to 1.75 × 10−5 mol L−1. Titrations were done manually using a micro-pipette in 2 min
intervals. Quenching values remained unchanged for more than 10 min after individual titrations.
3.6. Chinese Hamster Ovary Cell Cytotoxicity Assays
Cytotoxicity was evaluated on CHO cells utilizing a standard 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide (MTT) assay [49]. The MTT is a yellow tetrazolium salt that is
reduced to purple formazan in the presence of living cells. This reduction reaction was used to
measure growth and chemosensitivity. The test samples were tested in triplicate on one occasion.
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Cells were seeded in microtiter plates at a density of 105 cells/mL and incubated for 24 h prior to
exposure. The test samples were prepared to a 20 mg/mL stock solution in 10% methanol or 10%
DMSO and were tested as a suspension if not properly dissolved. Test compounds were stored at
−20 ◦C until use, and administered in volumes of 100 µL to the plated cells. Emetine was used as
the reference drug in all experiments. The highest concentration of each compound was 100 µg/mL,
which was serially diluted in complete medium with 10-fold dilutions to give 6 concentrations, the
lowest being 0.001 µg/L. The same dilution technique was applied to the all test samples. The highest
concentration of solvent had no measurable effect on the cell viability (data not shown). Plates were
developed after 44 h of exposure to the drug by the addition of a solution of MTT. After four hours,
further incubation at 37 ◦C the supernatant was removed from the cells via suction and DMSO was
added to each well to dissolve the reduced dye crystals. Plates were analysed at 540 nM wavelength
using a spectrophotometer to determine the relative amount of formazan salt in each well. The amount
of formazan produced in wells containing untreated cells only and growth medium only represent
100% survival and 0% survival respectively, and the amount in each treatment well was converted
to a survival percentage relative to these two extremes. The IC50 values were obtained from full
dose-response curves, using a non-linear dose-response curve fitting analysis via GraphPad Prism
v.4 software.
3.7. Human Neuroblastoma SH-SY5Y Cell Viability Assays
3.7.1. Cell Line and Culture Conditions
The human neuroblastoma cell line SH-SY5Y was generously donated by our collaborator
at the Division of Molecular Biology and Human Biology, Stellenbosch University, Tygerberg,
Cape Town. Cells were cultured in monolayer using Dulbecco Modified Eagles Medium (DMEM,
Gibco, Life Technologies Ltd. Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS,
Gibco, Life Technologies Ltd.) and 1% 100 U/mL penicillin and 100 µg/mL streptomycin (Lonza
Group Ltd., Basel, Switzerland). Cells were grown at 37 ◦C, in a humidified atmosphere at 5% CO2.
Media were replaced every two to three days and cells were sub-cultured by splitting with trypsin
(Lonza Group Ltd.).
3.7.2. SH-SY5Y Cytotoxicity Assays
The standard MTT assay which measures cell metabolic activity was used to determine
cytotoxicity of CM14, CM15 and CM9 as described by Mosmann [49]. Briefly, SH-SY5Y cells were
plated in flat bottom 96 well plates in growth medium as stated in Section 3.7.1 at a density of
7500 cells/well. Cells were allowed to adhere to the plate surface for 24 h and used media were
replaced with fresh media containing test compounds at 10 µM, 50 µM and 100 µM. Vehicle control
cells were treated with DMSO (solvent for dissolving test compounds) at a concentration similar to the
amount contained in the highest concentration of test compounds. After 48 h, 10 µL of MTT solution
(5 mg/mL) was added to each well and incubated for 4 h and the purple formazan formed was
solubilized with 100 µL DMSO and plates were read spectrophotometrically to determine absorbance
at 570 nm using a BMG Labtech POLARStar Omega multimodal plate reader.
3.7.3. MPP+-Induced Cytotoxicity in SH-SY5Y Cells
SH-SY5Y cells were seeded onto a 96-well plate and treated with 1000 µM MPP+ for approximately
48 h. Different concentrations (1 µM, 5 µM, and 10 µM) of test compounds were administrated two
hours prior to MPP+ treatment. Afterwards, cell viability was measured by MTT colorimetric assay
and performed as stated in Section 3.7.2.
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4. Conclusions
As part of a collaborative project, compounds from the University of the Western Cape, School
of Pharmacy drug-design group compound library were screened for antimycobacterial activity.
Various coumarin derivatives, originally designed and synthesized as multifunctional neuronal enzyme
inhibitors, demonstrated noteworthy antimycobacterial activity.
The coumarin CM9 substituted with an N-benzylpiperidine-containing moiety on the 7-position
and a 3-nitrile substitution on the coumarin nucleus showed the best MAO-B and ChE inhibitory
activities. This study identified that structural modification on position 4 and/or 7 of the coumarin
scaffold can be utilized to improve selectivity towards either inhibition of neuronal enzymes
or antimycobacterial effect. Large substitutions on position 4 (4-trifluoromethyl moiety) and
p-bromo-N-benzylpiperazine compared to N-benzylpiperidine substitutions on position 7 increase
activity against M. tuberculosis but inversely affect monoamine oxidase and cholinesterase inhibition.
After validation of the antimycobacterial activity observed in the MTS; CM8, CM12, CM14
(4-metyl substituted) and CM15 (4-trifluoromethyl-substituted) were identified as the most active
compounds in the series. In addition to activity in standard M. tuberculosis H37Rv, we also described
activity of selected coumarin derivatives in fluoroquinolone resistant bacteria. Evaluations on three
moxifloxacin resistant strains harboring mutations in the QRDR of DNA gyrase indicate that the
compound in series 1 will likely maintain potency in fluoroquinolone resistant mycobacteria.
The MICs of the four most active compounds were evaluated using two methods
i.e., M. tuberculosis H37RvMA pMSP12:GFP in GAST-Fe media [32], and M. tuberculosis
H37Rv:pCHERRY3 [31] in 7H9+OADC. The MIC values in the GAST-Fe assay were consistently
lower (2–3 fold lower for CM8, CM12, and CM14 and 14 fold lower for CM15). Difference in inoculum
size and the lack and presence of albumin in GAST-Fe and 7H9+OADC media respectively were
suggested as primary contributing factors to the MIC variations.
As coumarin derivatives are known to bind extensively to blood-soluble proteins, albumin
binding properties of CM15 and CM14 (with the highest and lowest MIC fold difference between
assays respectively) were evaluated. Fluorescence quenching of BSA in response to compound binding
was evaluated in the presence of various concentrations of the compounds. Analysis of fluorescence
quenching of tryptophan in BSA indicate that both CM14 and CM15 form concentration dependant
complexes with BSA. These results suggest that albumin binding plays a large role in the observed
differences in activity between the GAST-Fe and 7H9+OADC assays used in this study. The more
extensive decrease in fluorescence observed with CM15 likely indicates a higher binding affinity
between CM15 and thus explains the large MIC differences observed for this compound. This report
therefore highlights the importance of early consideration of plasma binding properties of coumarin
derivatives as it was shown here to influence in vitro evaluations in addition to its more commonly
considered effect on in vivo, and future pharmacokinetic behavior of the compounds.
CM8, CM12, CM14, and CM15 showed moderate (CC50: 15.5–41.2 µM) cytotoxicity compared
to the cytotoxic agent emetine (CC50 = 0.06 µM). These compounds however showed low selectivity
indices when both the GFP and mCHERRY MIC99 assay results are compared to the CC50 results
(Table 4). The compounds, in general, were slightly more selective towards the mycobacterial strain
when using the GFP assay results, with CM15 showing the best selectivity (SI = 3.16). The slight
selectivity was however not retained when the results from the mCHERRY assay were used in the
SI calculations. These poor selectivity indices may limit the further development of these coumarin
derivatives. However, the structure-activity relationships identified in this paper may enable the
design of coumarin structures with improved antimycobacterial activities and subsequently more
favourable selectivity indices.
The viability of SHSY-5Y human neuroblastoma cells was also assessed at different concentrations
of compounds CM9, CM14, or CM15. Treatment with the compounds at 10 µM did not significantly
affect the viability of the SH-SY5Y cells (p > 0.05). However, at higher concentrations (50 µM and
100 µM) the viability of the cells was significantly (p < 0.001) affected. Neuroprotective ability of
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the three compounds were therefore evaluated at concentrations between 1 µM and 10 µM. CM9,
CM14, and CM15 all demonstrated significant and comparable cytoprotection towards MPP+ insults
to the SH-SY5Y neural cells. As these compounds differ significantly in their neuronal enzyme
inhibitory activity it can be concluded that enzyme inhibition is not the only factor that plays a role in
cytoprotection and that other mechanisms of action are involved in the observed neuroprotection.
This article therefore describes the versatile neuronal enzyme inhibitory, neuroprotective and
antimycobacterial nature of a range of coumarin derivatives. Importantly, comparison of corresponding
structure-activity relationship, demonstrates that it is possible to reduce the promiscuous activity
of the derivatives through careful modification on the coumarin scaffold. Furthermore the article
highlights the importance of broader evaluation of pharmacological effects of coumarin derivatives
over and above cytotoxicity assays to identify and afford early limitation of unwanted pharmacological
effects. This report also shows that albumin binding properties of coumarin derivatives may impact on
in vitro assay results and should therefore be taken into consideration even during early evaluations
of coumarin-type compounds.
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